S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
NASDAQ:CNTB

Connect Biopharma (CNTB) Competitors

$0.73
+0.08 (+12.35%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.55
▼
$0.82
50-Day Range
$0.65
▼
$1.13
52-Week Range
$0.53
▼
$1.58
Volume
182,349 shs
Average Volume
16,568 shs
Market Capitalization
$40.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

CNTB vs. PASG, CKPT, SLNO, LVTX, LPTX, QNCX, BIOR, UBX, ACHL, and ALGS

Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Passage Bio (PASG), Checkpoint Therapeutics (CKPT), Soleno Therapeutics (SLNO), LAVA Therapeutics (LVTX), Leap Therapeutics (LPTX), Quince Therapeutics (QNCX), Biora Therapeutics (BIOR), Unity Biotechnology (UBX), Achilles Therapeutics (ACHL), and Aligos Therapeutics (ALGS). These companies are all part of the "medical" sector.

Connect Biopharma vs.

Passage Bio (NASDAQ:PASG) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Passage Bio's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Passage BioN/A -60.01% -48.67%
Connect Biopharma N/A N/A N/A

61.6% of Passage Bio shares are held by institutional investors. Comparatively, 18.8% of Connect Biopharma shares are held by institutional investors. 12.4% of Passage Bio shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/A-$136.13M-$2.06-0.33
Connect BiopharmaN/AN/A-$114.44MN/AN/A

Passage Bio has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Connect Biopharma has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500.

Passage Bio received 31 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 66.67% of users gave Connect Biopharma an outperform vote while only 65.22% of users gave Passage Bio an outperform vote.

CompanyUnderperformOutperform
Passage BioOutperform Votes
45
65.22%
Underperform Votes
24
34.78%
Connect BiopharmaOutperform Votes
14
66.67%
Underperform Votes
7
33.33%

Passage Bio presently has a consensus target price of $8.40, suggesting a potential upside of 1,144.26%. Connect Biopharma has a consensus target price of $6.00, suggesting a potential upside of 724.18%. Given Connect Biopharma's higher possible upside, analysts clearly believe Passage Bio is more favorable than Connect Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Passage Bio
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Connect Biopharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Connect Biopharma had 2 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for Connect Biopharma and 0 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.75 beat Connect Biopharma's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Passage Bio Neutral
Connect Biopharma Positive

Summary

Connect Biopharma beats Passage Bio on 7 of the 12 factors compared between the two stocks.


Get Connect Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNTB vs. The Competition

Export to Excel
MetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$40.07M$5.88B$4.50B$6.27B
Dividend YieldN/A2.75%2.58%6.51%
P/E RatioN/A4.86116.6812.22
Price / SalesN/A176.662,870.7670.24
Price / CashN/A20.7193.03100.49
Price / Book0.253.733.764.83
Net Income-$114.44M$199.54M$122.24M$186.05M
7 Day Performance-4.22%-5.73%-2.61%-3.10%
1 Month Performance-11.23%-9.30%-3.60%-5.68%
1 Year Performance-38.31%8.44%9.51%5.50%

Connect Biopharma Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PASG
Passage Bio
2.4136 of 5 stars		$0.76
flat		$8.40
+1,003.8%		-47.3%$41.71MN/A-0.3785Positive News
CKPT
Checkpoint Therapeutics
1.8304 of 5 stars		$1.97
-1.5%		$24.80
+1,158.9%		-85.3%$42.53M$190,000.000.0024News Coverage
SLNO
Soleno Therapeutics
2.4464 of 5 stars		$4.00
-2.7%		$13.50
+237.5%		+135.2%$39.96MN/A-1.3225News Coverage
LVTX
LAVA Therapeutics
1.8395 of 5 stars		$1.72
+1.2%		$13.33
+675.2%		-36.7%$43.60M$24.26M-1.1269News Coverage
LPTX
Leap Therapeutics
2.1667 of 5 stars		$1.73
-10.4%		$18.80
+986.7%		-85.4%$44.24M$1.50M-0.2744Gap Up
QNCX
Quince Therapeutics
0 of 5 stars		$1.23
-3.1%		N/A-10.9%$44.75MN/A0.0021News Coverage
Positive News
Gap Down
BIOR
Biora Therapeutics
1.5234 of 5 stars		$2.75
-6.8%		N/A-99.4%$38.18M$98,000.00-0.5054Positive News
Gap Up
UBX
Unity Biotechnology
2.0147 of 5 stars		$2.51
+1.2%		$6.75
+168.9%		-39.0%$36.65M$240,000.00-0.6322Positive News
ACHL
Achilles Therapeutics
2.0174 of 5 stars		$0.89
+4.7%		$9.50
+968.6%		-68.7%$36.40MN/A-0.50234News Coverage
ALGS
Aligos Therapeutics
2.4671 of 5 stars		$0.80
-3.6%		$4.00
+400.0%		-28.2%$34.80M$17.25M-0.4268News Coverage
Positive News
Gap Down

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:CNTB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -